share_log

Panbela Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Panbela Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Panbela Therapeutics | PRE 14A：并购重组委托声明
SEC announcement ·  03/25 16:22
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually in 2024, with the exact date yet to be determined. The meeting will address two key proposals: a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-45, and the potential adjournment of the meeting if necessary to solicit additional proxies. Stockholders of record as of March 27, 2024, will be eligible to vote. The reverse stock split aims to increase the per-share market price of Panbela's common stock to meet national securities exchange listing requirements and avoid penny stock classification. This follows the Nasdaq Hearings Panel's decision to delist Panbela's common stock, which was suspended from trading on March 7, 2024, and is now quoted on the OTC Pink market. The Board of Directors has unanimously approved the proposals and recommends stockholders vote in favor. The proposals are detailed in the proxy statement, which will be distributed starting on or about the date of the announcement.
Panbela Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually in 2024, with the exact date yet to be determined. The meeting will address two key proposals: a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-45, and the potential adjournment of the meeting if necessary to solicit additional proxies. Stockholders of record as of March 27, 2024, will be eligible to vote. The reverse stock split aims to increase the per-share market price of Panbela's common stock to meet national securities exchange listing requirements and avoid penny stock classification. This follows the Nasdaq Hearings Panel's decision to delist Panbela's common stock, which was suspended from trading on March 7, 2024, and is now quoted on the OTC Pink market. The Board of Directors has unanimously approved the proposals and recommends stockholders vote in favor. The proposals are detailed in the proxy statement, which will be distributed starting on or about the date of the announcement.
Panbela Therapeutics, Inc.宣布将在2024年虚拟举行股东特别会议，具体日期尚未确定。会议将讨论两项关键提案：以1比10和1比45的比例反向拆分公司普通股，以及在必要时可能休会以寻求更多代理人。截至2024年3月27日的登记股东将有资格投票。反向股票拆分旨在提高Panbela普通股的每股市场价格，以满足国家证券交易所的上市要求并避免细价股的分类。在此之前，纳斯达克听证会小组决定将Panbela的普通股退市，该普通股于2024年3月7日暂停交易，现已在场外粉红市场上市。董事会一致批准了这些提案，并建议股东投赞成票。委托书中详细介绍了这些提案，委托书将在公告发布之日或前后分发。
Panbela Therapeutics, Inc.宣布将在2024年虚拟举行股东特别会议，具体日期尚未确定。会议将讨论两项关键提案：以1比10和1比45的比例反向拆分公司普通股，以及在必要时可能休会以寻求更多代理人。截至2024年3月27日的登记股东将有资格投票。反向股票拆分旨在提高Panbela普通股的每股市场价格，以满足国家证券交易所的上市要求并避免细价股的分类。在此之前，纳斯达克听证会小组决定将Panbela的普通股退市，该普通股于2024年3月7日暂停交易，现已在场外粉红市场上市。董事会一致批准了这些提案，并建议股东投赞成票。委托书中详细介绍了这些提案，委托书将在公告发布之日或前后分发。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息